English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are idiopathic chronic intestinal inflammatory diseases, characterized by recurrent episodes of relapse and remission of disease. The introduction of anti-tumor necrosis factor (anti-TNF) agents has greatly improved the treatment outcomes for IBDs, enabling higher rates of clinical and endoscopic remission in patients who are refractory to conventional therapies such as corticosteroids and thiopurines.1,2 Despite the proven therapeutic efficacy of anti-TNF agents, treatment failures to those sometimes occur in the form of primary nonresponse or secondary loss of response (LOR).

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?